Ann: Comment on research report, page-173

First 173 Last

Share
Profile

Follow
cheesepope

5,946 Posts.

355

18/02/24

10:46

Post #: 72467483
Share

Originally posted by santo.nath: ↑

https://www.********.au/2024/02/17/a-hot-asx-stock-with-multiple-catalysts-looming-is-8-down-time-to-buy/ (replace xxxxxx with fool)

A hot ASX stock with 'multiple catalysts' looming is 8% down.

Time to buy

The Blackwattle team is still bullish on these pharmaceutical shares despite a recent sell-off.

It's funny to call an ASX stock that's rocketed 217% in the past year a "bargain".

But that's precisely the situation we have with Neuren Pharmaceuticals Ltd (ASX: NEU), according to the experts at Blackwattle.

Let's check out their rationale:

'A pause for breath'
The Neuren share price has plunged 8.2% since late December.

But the simple fact is that the Blackwattle team is not worried.

"Neuren fell 5% in January, which we saw as a pause for breath, after rising 115% over the previous 3 months," read its memo to clients.

The steep climb in the preceding quarter was due to multiple factors.

"The rise over the previous three months was driven by the release of strong revenue growth from Daybue, their sole approved drug treating Rett Syndrome in the US and positive phase 2 trial results for their new drug NNZ-2591."

The new drug development is critical in the Blackwattle team's continued bullishness.

"The phase 2 results for NNZ-2591 were particularly exciting and provide strong confidence for NNZ-2591 to progress towards a phase 3 trial."

A huge 2024 expected for this ASX stock
Blackwattle experts are far from the only ones not at all put off by either the massive rise in the past year or the diving stock price over the past six weeks.

Broking platform CMC Invest shows all five analysts covering Neuren still rating the stock as a buy.

"We continue to retain a large position in the company given the multiple value accretive upcoming catalysts in 2024," read the memo.

"The key drivers for the portfolio tend to be fundamental company updates which give high quality companies the opportunity to demonstrate their ongoing strength and the market can reassess the outlook and what to pay for it."

Neuren Pharmaceuticals is scheduled to release its preliminary financial results on 23 February.

Expand

Your number one asset is a failure with serious side effects and likely to be pulled and it is time to buy more.ok

NEU Price at posting: $19.78 Sentiment: Sell Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

MEM

Many are concerned about global falling birthrates. This diverse stock has solutions

Almonty Industries – Now it is getting critical!

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

LU7

Lithium Universe leaps 40% after buying rights to flashy solar panel recycling tech

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

First 173 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $13.08		Change 0.225(1.75%)		Mkt cap ! $1.626B

Open	High	Low	Value	Volume
$13.15	$13.37	$12.92	$5.698M	434.5K

Buyers (Bids)

No.	Vol.	Price($)
12	191	$13.07

Sellers (Offers)

Price($)	Vol.	No.
$13.08	422	10

View Market Depth

No.	Vol.	Price($)
27	975	13.070
9	696	13.060
16	1487	13.050
8	1603	13.040
8	2969	13.030

Price($)	Vol.	No.
13.080	346	7
13.090	565	8
13.100	1243	9
13.110	1510	11
13.120	1647	6

Last trade - 14.51pm 18/06/2025 (20 minute delay)

NEU (ASX) Chart

Ann: Comment on research report, page-173

Many are concerned about global falling birthrates. This diverse stock has solutions

Almonty Industries – Now it is getting critical!

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Lithium Universe leaps 40% after buying rights to flashy solar panel recycling tech

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Comment on research report, page-173

Top Stories

Many are concerned about global falling birthrates. This diverse stock has solutions

Almonty Industries – Now it is getting critical!

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Lithium Universe leaps 40% after buying rights to flashy solar panel recycling tech

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News